Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept (Q33213561)

24 July 2017

title

Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept (English)

1 reference

24 July 2017

Wolff D

1 reference

24 July 2017

Roessler V

1 reference

24 July 2017

Steiner B

1 reference

24 July 2017

Wilhelm S

1 reference

24 July 2017

Weirich V

1 reference

24 July 2017

Brenmoehl J

1 reference

24 July 2017

Leithaeuser M

1 reference

24 July 2017

Hofmeister N

1 reference

24 July 2017

Junghanss C

1 reference

24 July 2017

Casper J

1 reference

24 July 2017

Hartung G

1 reference

24 July 2017

Holler E

1 reference

24 July 2017

Freund M

1 reference

24 July 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

Bone Marrow Transplantation

24 July 2017

published in

1 reference

24 July 2017

1 reference

24 July 2017

1 reference

24 July 2017

page(s)

1003-1010

1 reference

Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment

24 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704929

Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704929

Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704929

A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704929

Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704929

Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704929

Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704929

Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704929

Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704929

Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704929

Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704929

Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704929

Infliximab for steroid‐refractory acute GVHD: A case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704929

Infliximab for the treatment of severe steroid refractory acute graft-versus-host disease in three patients after allogeneic hematopoietic transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704929

Etanercept (Enbrel) administration for idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704929

Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704929

Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704929

Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704929

Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704929

Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704929

Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704929

Chronic graft-versus-host disease after allogeneic blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704929

Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704929

TUMOR NECROSIS FACTOR-?? NEUTRALIZATION REDUCES LUNG INJURY AFTER EXPERIMENTAL ALLOGENEIC BONE MARROW TRANSPLANTATION1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704929

Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704929

inferred from DOI database lookup

7 January 2021

based on heuristic

Etanercept in graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704929

inferred from DOI database lookup

7 January 2021

based on heuristic

Cerebral toxoplasmosis following etanercept treatment for idiophatic pneumonia syndrome after autologous peripheral blood progenitor cell transplantation (PBPCT)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704929

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.BMT.1704929

1 reference

Dimensions Publication ID

24 July 2017

1045806031

0 references

1 reference